Have a feature idea you'd love to see implemented?
Let us know!
IMCR Immunocore Holdings plc
Price (delayed)
$32.12
Market cap
$1.61B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.94
Enterprise value
$1.55B
immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of
Highlights
The EPS has grown by 34% year-on-year and by 14% since the previous quarter
IMCR's net income is up by 32% YoY and by 14% QoQ
Immunocore Holdings's quick ratio has decreased by 27% from the previous quarter and by 15% YoY
Key stats
What are the main financial stats of IMCR
Market
Valuations
Earnings
Shares outstanding
50.03M
Market cap
$1.61B
Enterprise value
$1.55B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.25
Price to sales (P/S)
5.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.24
Revenue
$295.84M
EBIT
-$42.8M
EBITDA
-$37.64M
Free cash flow
$41.74M
Per share
Balance sheet
Liquidity
EPS
-$0.94
Free cash flow per share
$0.83
Book value per share
$7.55
Revenue per share
$5.91
TBVPS
$21.68
Total assets
$1.08B
Total liabilities
$706.81M
Debt
$481.06M
Equity
$377.83M
Working capital
$739.66M
Debt to equity
1.27
Current ratio
3.78
Quick ratio
3.62
Net debt/EBITDA
1.51
Margins
Efficiency
Dividend
EBITDA margin
-12.7%
Gross margin
99.4%
Net margin
-15.7%
Operating margin
-23.1%
Return on assets
-5%
Return on equity
-12.7%
Return on invested capital
-8%
Return on capital employed
-5.2%
Return on sales
-14.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMCR stock price
How has the Immunocore Holdings stock price performed over time
Intraday
-0.93%
1 week
-1.53%
1 month
-3.57%
1 year
-28.86%
YTD
-52.99%
QTD
3.18%
Financial performance
How have Immunocore Holdings's revenue and profit performed over time
Revenue
$295.84M
Gross profit
$294M
Operating income
-$68.33M
Net income
-$46.52M
Gross margin
99.4%
Net margin
-15.7%
The net margin has grown by 46% YoY and by 19% from the previous quarter
IMCR's net income is up by 32% YoY and by 14% QoQ
The operating margin rose by 26% YoY and by 13% QoQ
The revenue is up by 26% year-on-year and by 5% since the previous quarter
Growth
What is Immunocore Holdings's growth rate over time
Valuation
What is Immunocore Holdings stock price valuation
P/E
N/A
P/B
4.25
P/S
5.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.24
The EPS has grown by 34% year-on-year and by 14% since the previous quarter
IMCR's price to book (P/B) is 38% less than its last 4 quarters average of 6.8
The equity rose by 5% since the previous quarter and by 3.7% year-on-year
The stock's price to sales (P/S) is 41% less than its last 4 quarters average of 9.2
The revenue is up by 26% year-on-year and by 5% since the previous quarter
Efficiency
How efficient is Immunocore Holdings business performance
The ROIC has soared by 79% YoY and by 42% QoQ
The return on assets has surged by 60% year-on-year and by 26% since the previous quarter
The ROE is up by 35% year-on-year and by 15% since the previous quarter
The return on sales has grown by 20% since the previous quarter and by 5% year-on-year
Dividends
What is IMCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMCR.
Financial health
How did Immunocore Holdings financials performed over time
The total assets is 53% greater than the total liabilities
The total assets has surged by 87% year-on-year and by 6% since the previous quarter
The current ratio fell by 27% QoQ and by 11% YoY
The debt is 27% more than the equity
The equity rose by 5% since the previous quarter and by 3.7% year-on-year
The debt to equity is down by 3.8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.